Yang et al. recently studied the feasibility of a multi-modal liquid biopsy approach, which included tumor-associated EV miRNA and mRNA, cfDNA, cfDNA KRAS mutations, and CA19-9, for early diagnosis of pancreatic cancer in 204 subjects [56]. Here, KRAS is linked to familial pancreatic carcinoma.